1. Home
  2. EMBC vs OCS Comparison

EMBC vs OCS Comparison

Compare EMBC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMBC
  • OCS
  • Stock Information
  • Founded
  • EMBC 1924
  • OCS 2003
  • Country
  • EMBC United States
  • OCS Switzerland
  • Employees
  • EMBC N/A
  • OCS N/A
  • Industry
  • EMBC Medical/Dental Instruments
  • OCS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMBC Health Care
  • OCS Health Care
  • Exchange
  • EMBC Nasdaq
  • OCS Nasdaq
  • Market Cap
  • EMBC 716.2M
  • OCS 689.8M
  • IPO Year
  • EMBC N/A
  • OCS N/A
  • Fundamental
  • Price
  • EMBC $11.97
  • OCS $18.58
  • Analyst Decision
  • EMBC Hold
  • OCS Strong Buy
  • Analyst Count
  • EMBC 3
  • OCS 4
  • Target Price
  • EMBC $17.67
  • OCS $31.50
  • AVG Volume (30 Days)
  • EMBC 445.0K
  • OCS 28.3K
  • Earning Date
  • EMBC 05-09-2025
  • OCS 05-08-2025
  • Dividend Yield
  • EMBC 5.02%
  • OCS N/A
  • EPS Growth
  • EMBC N/A
  • OCS N/A
  • EPS
  • EMBC 0.89
  • OCS N/A
  • Revenue
  • EMBC $1,079,500,000.00
  • OCS $847,333.00
  • Revenue This Year
  • EMBC N/A
  • OCS $49.27
  • Revenue Next Year
  • EMBC $0.99
  • OCS $1,920.31
  • P/E Ratio
  • EMBC $13.36
  • OCS N/A
  • Revenue Growth
  • EMBC N/A
  • OCS N/A
  • 52 Week Low
  • EMBC $10.12
  • OCS $10.79
  • 52 Week High
  • EMBC $21.48
  • OCS $23.08
  • Technical
  • Relative Strength Index (RSI)
  • EMBC 46.46
  • OCS 54.68
  • Support Level
  • EMBC $12.08
  • OCS $18.01
  • Resistance Level
  • EMBC $13.45
  • OCS $19.50
  • Average True Range (ATR)
  • EMBC 0.59
  • OCS 0.77
  • MACD
  • EMBC 0.13
  • OCS 0.17
  • Stochastic Oscillator
  • EMBC 40.75
  • OCS 66.30

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Share on Social Networks: